Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Enmetazobactam (AAI101) 是一种广谱β-lactamase 抑制剂,有抗耐药革兰氏阴性细菌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 282 | 现货 | ||
2 mg | ¥ 393 | 现货 | ||
5 mg | ¥ 662 | 现货 | ||
10 mg | ¥ 1,070 | 现货 | ||
25 mg | ¥ 1,890 | 现货 | ||
50 mg | ¥ 2,980 | 现货 | ||
100 mg | ¥ 4,480 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 728 | 现货 |
产品描述 | Enmetazobactam (AAI101) is an extended-spectrum β-lactamase inhibitor for the treatment of multi-drug resistant gram-negative bacterial infections. |
体外活性 | Enmetazobactam是一种新型的扩展谱β-内酰胺酶抑制剂。在223个对头孢吡肟不敏感的分离株中,95%对头孢他啶不敏感,49%对依他培南不敏感,57%对哌拉西林/他唑巴坦不敏感,90%属于多重耐药(对3类药物耐药),22%产生碳青霉烯酶,67%产生ESBLs。添加Enmetazobactam后,能显著降低头孢吡肟的最小抑菌浓度(MIC50),从>64 mg/L降至头孢吡肟/Enmetazobactam的0.13 mg/L,支持其在治疗这些微生物引起的感染中继续开发使用。Enmetazobactam对特定耐药表型表现出强大的活性,其MIC50和MIC90分别为0.125 mg/L和64 mg/L[1]。对于大多数菌株,随着Enmetazobactam浓度的增加(在1至16 mg/L范围内),头孢吡肟-Enmetazobactam的MICs显示出降低趋势,这表明Enmetazobactam在恢复头孢菌素类抗菌活性方面呈现浓度依赖性[1]。 |
体内活性 | Against a panel of 20 mostly carbapenemase-producing cefepime-nonsusceptible strains of the family Enterobacteriaceae, we evaluated the MICs of cefepime in the presence of various fixed AAI101 concentrations (1, 2, 4, 8, and 16 mg/liter) and the in vivo efficacy of simulated human doses of cefepime and cefepime-AAI101 in a neutropenic murine thigh infection model.?At 2 h after inoculation, mice were dosed with regimens that provided a profile mimicking the free drug concentration-time profile observed in humans given cefepime at 2 g every 8 h (q8h;?as a 30-min infusion) or cefepime-AAI101 at 2 g/0.5 g q8h (as a 30-min infusion).?Efficacy was determined by calculation of the change in thigh bacterial density (log10 number of CFU) after 24 h relative to the starting inoculum (0 h). After 24 h, bacterial growth of 2.7 0.1 log10 CFU (mean standard error) was observed in control animals.?Efficacy for cefepime monotherapy was observed against only 3 isolates, whereas increases in bacterial density similar to that in the control animals were noted for the remaining 17 strains (all with cefepime MICs of 64 mg/liter).?The humanized cefepime-AAI101 dosing regimen resulted in bacterial reductions of 0.5 log10 CFU for 12 of the 20 strains[2]. |
别名 | AAI101 |
分子量 | 314.32 |
分子式 | C11H14N4O5S |
CAS No. | 1001404-83-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 113.3 mg/mL (360.46 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1815 mL | 15.9074 mL | 31.8147 mL | 79.5368 mL |
5 mM | 0.6363 mL | 3.1815 mL | 6.3629 mL | 15.9074 mL | |
10 mM | 0.3181 mL | 1.5907 mL | 3.1815 mL | 7.9537 mL | |
20 mM | 0.1591 mL | 0.7954 mL | 1.5907 mL | 3.9768 mL | |
50 mM | 0.0636 mL | 0.3181 mL | 0.6363 mL | 1.5907 mL | |
100 mM | 0.0318 mL | 0.1591 mL | 0.3181 mL | 0.7954 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Enmetazobactam 1001404-83-6 Microbiology/Virology Antibacterial Bacterial inhibit AAI-101 AAI 101 AAI101 Inhibitor inhibitor